These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). Keller M; Bush E; Diamond JM; Shah P; Matthew J; Brown AW; Sun J; Timofte I; Kong H; Tunc I; Luikart H; Iacono A; Nathan SD; Khush KK; Orens J; Jang M; Agbor-Enoh S J Heart Lung Transplant; 2021 Jun; 40(6):488-493. PubMed ID: 33814284 [TBL] [Abstract][Full Text] [Related]
18. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. Gallagher HM; Sarwar G; Tse T; Sladden TM; Hii E; Yerkovich ST; Hopkins PM; Chambers DC J Heart Lung Transplant; 2015 Nov; 34(11):1442-8. PubMed ID: 26186804 [TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK). Fisher AJ; White M; Goudie N; Kershaw A; Phillipson J; Bardgett M; Lally J; Bevin-Nicholls A; Chadwick T; Bryant A; Russell S; Smith H; Frisby L; Errington R; Carby M; Thompson R; Santhanakrishnan K; Parmar J; Lordan JL; Vale L; Hancock H; Exley C; Gennery AR; Wason JM BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38724453 [TBL] [Abstract][Full Text] [Related]